Comprehensive analysis of kinase inhibitor selectivity

被引:1600
作者
Davis, Mindy I. [1 ]
Hunt, Jeremy P. [1 ]
Herrgard, Sanna [1 ]
Ciceri, Pietro [1 ]
Wodicka, Lisa M. [1 ]
Pallares, Gabriel [1 ]
Hocker, Michael [1 ]
Treiber, Daniel K. [1 ]
Zarrinkar, Patrick P. [1 ]
机构
[1] Ambit Biosci, San Diego, CA USA
关键词
INTERACTION MAP; KINOME; BINDING;
D O I
10.1038/nbt.1990
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome. Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend. The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compounds tested. Analysis of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily. The data set suggests compounds to use as tools to study kinases for which no dedicated inhibitors exist. It also provides a foundation for further exploring kinase inhibitor biology and toxicity, as well as for studying the structural basis of the observed interaction patterns. Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.
引用
收藏
页码:1046 / U124
页数:7
相关论文
共 30 条
  • [1] The specificities of protein kinase inhibitors: an update
    Bain, J
    McLauchlan, H
    Elliott, M
    Cohen, P
    [J]. BIOCHEMICAL JOURNAL, 2003, 371 : 199 - 204
  • [2] Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery
    Bamborough, Paul
    Drewry, David
    Harper, Gavin
    Smith, Gary K.
    Schneider, Klaus
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (24) : 7898 - 7914
  • [3] Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
    Bantscheff, Marcus
    Eberhard, Dirk
    Abraham, Yann
    Bastuck, Sonja
    Boesche, Markus
    Hobson, Scott
    Mathieson, Toby
    Perrin, Jessica
    Raida, Manfred
    Rau, Christina
    Reader, Valerie
    Sweetman, Gavain
    Bauer, Andreas
    Bouwmeester, Tewis
    Hopf, Carsten
    Kruse, Ulrich
    Neubauer, Gitte
    Ramsden, Nigel
    Rick, Jens
    Kuster, Bernhard
    Drewes, Gerard
    [J]. NATURE BIOTECHNOLOGY, 2007, 25 (09) : 1035 - 1044
  • [4] SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
    Buchanan, Sean G.
    Hendle, Jorg
    Lee, Patrick S.
    Smith, Christopher R.
    Bounaud, Pierre-Yves
    Jessen, Katti A.
    Tang, Crystal M.
    Huser, Nanni H.
    Felce, Jeremy D.
    Froning, Karen J.
    Peterman, Marshall C.
    Aubol, Brandon E.
    Gessert, Steve F.
    Sauder, Michael
    Schwinn, Kenneth D.
    Russell, Marijane
    Rooney, Isabelle A.
    Adams, Jason
    Leon, Barbara C.
    Do, Tuan H.
    Blaney, Jeff M.
    Sprengeler, Paul A.
    Thompson, Devon A.
    Smyth, Lydia
    Pelletier, Laura A.
    Atwell, Shane
    Holme, Kevin
    Wasserman, Stephen R.
    Emtage, Spencer
    Burley, Stephen K.
    Reich, Siegfried H.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12) : 3181 - 3190
  • [5] Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors
    Carlomagno, F
    Guida, T
    Anaganti, S
    Vecchio, G
    Fusco, A
    Ryan, AJ
    Billaud, M
    Santoro, M
    [J]. ONCOGENE, 2004, 23 (36) : 6056 - 6063
  • [6] Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2
    Deng, Xianming
    Dzamko, Nicolas
    Prescott, Alan
    Davies, Paul
    Liu, Qingsong
    Yang, Qingkai
    Lee, Jiing-Dwan
    Patricelli, Matthew P.
    Nomanbhoy, Tyzoon K.
    Alessi, Dario R.
    Gray, Nathanael S.
    [J]. NATURE CHEMICAL BIOLOGY, 2011, 7 (04) : 203 - 205
  • [7] A small molecule-kinase interaction map for clinical kinase inhibitors
    Fabian, MA
    Biggs, WH
    Treiber, DK
    Atteridge, CE
    Azimioara, MD
    Benedetti, MG
    Carter, TA
    Ciceri, P
    Edeen, PT
    Floyd, M
    Ford, JM
    Galvin, M
    Gerlach, JL
    Grotzfeld, RM
    Herrgard, S
    Insko, DE
    Insko, MA
    Lai, AG
    Lélias, JM
    Mehta, SA
    Milanov, ZV
    Velasco, AM
    Wodicka, LM
    Patel, HK
    Zarrinkar, PP
    Lockhart, DJ
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (03) : 329 - 336
  • [8] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
    Fedorov, Oleg
    Marsden, Brian
    Pogacic, Vanda
    Rellos, Peter
    Mueller, Susanne
    Bullock, Alex N.
    Schwaller, Juerg
    Sundstrom, Michael
    Knapp, Stefan
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (51) : 20523 - 20528
  • [9] High-throughput kinase profiling as a platform for drug discovery
    Goldstein, David M.
    Gray, Nathanael S.
    Zarrinkar, Patrick P.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (05) : 391 - 397
  • [10] The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro
    Hasinoff, Brian B.
    Patel, Daywin
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2010, 249 (02) : 132 - 139